AGILE (Early Phase Platform Trial for COVID-19)

  • STATUS
    Recruiting
  • End date
    Apr 30, 2024
  • participants needed
    600
  • sponsor
    University of Liverpool
Send
Updated on 4 July 2022
See if I qualify

Summary

The AGILE platform master protocol allows incorporation of a range of identified and yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the trial. Candidates will be added into the trial via candidate-specific trial (CST) protocols of this master protocol as appendices. Having one master protocol ensures different candidates are evaluated in the same consistent manor and opening up new trials for new candidates is more efficient. Inclusion of new candidates will be determined by the AGILE Scientific Advisory Board based on pre-clinical data, evidence in the clinical setting and GMP capabilities.

Description

AGILE is a multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II Bayesian randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19.

This study allows for the assessment of many candidates at different doses, with the ability to add candidates as they are identified or drop them as their evaluation is completed. Promising candidates will move to the an external trial for further evaluation in the phase II/III setting.

Each candidate will be evaluated in its own trial, randomising between candidate and control with 2:1 allocation in favour of the candidate. Each dose will be assessed for safety sequentially in cohorts of 6 patients. Once a phase II dose has been identified we will assess efficacy by seamlessly expanding into a larger cohort.

AGILE is completely flexible in that the core design in the master protocol (as has been explained above) can be adapted for each candidate based on prior knowledge of the candidate

  • i.e. population, primary endpoint and sample size can be amended. This will be detailed in each candidate-specific trial protocol of the master protocol.

Candidate-Specific Trial 2 (CST-2): Open-label 2:1 randomised controlled phase I of EIDD-2801 versus standard of care followed by a 1:1 blinded controlled parallel group Phase II trial of EIDD-2801 versus placebo. A phase I will be carried out to confirm the optimal dose in this group. Following a safety review, EIDD-2801 will be tested for efficacy in a blinded placebo controlled randomised phase II trial.

Candidate-Specific Trial 3 (CST-3A): Multicentre, Adaptive, Phase I trial to Determine the optimal dose, Safety and Efficacy of Nitazoxanide for the Treatment of COVID-19

Candidate-Specific Trial 3 (CST-3B): A Randomized, Multicentre, Seamless, Adaptive, Phase I/II trial to Determine the optimal dose, Safety and Efficacy of Nitazoxanide for the Treatment of COVID-19

Candidate-Specific Trial 5 (CST-5): Randomized, Multicentre, Seamless, Adaptive, Phase I/II Platform Study to Determine the Phase II dose of VIR-7832, and Evaluate the Safety and Efficacy of VIR-7831 and VIR-7832 for the Treatment of COVID-19

Details
Condition Covid19
Treatment Nitazoxanide, VIR-7831, CST-2: EIDD-2801, CST-2: Placebo, VIR-7832, CST-5: Placebo
Clinical Study IdentifierNCT04746183
SponsorUniversity of Liverpool
Last Modified on4 July 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Adults (≥18 years) with laboratory-confirmed SARS-CoV-2 infection (PCR)
Ability to provide informed consent signed by study patient or legally acceptable representative
Women of childbearing potential (WOCBP) and male patients who are sexually active with WOCBP must agree to use a highly effective method of contraception (as outlined in the protocol) from the first administration of trial treatment, throughout trial treatment and for the duration outlined in the candidate-specific trial protocol after the last dose of trial treatment
If any CSTs are included in the community setting, the CST protocol will clarify whether patients with suspected SARS-CoV-2 infection are also eligible
Standard additional criteria that may be applied per CST protocol
Group A (severe disease) 4a. Patients with clinical status of Grades 4 (hospitalised
oxygen by mask or nasal prongs), 5 (hospitalised, on non-invasive ventilation, or high flow
oxygen), 6 (hospitalised, intubation and mechanical ventilation) or 7 (ventilation and
additional organ support - pressors, renal replacement therapy (RRT), extracorporeal
membrane oxygenation (ECMO)), as defined by the WHO clinical severity score, 9-point
ordinal scale
Group B (mild-moderate disease) 4b. Ambulant or hospitalised patients with the following
characteristics peripheral capillary oxygen saturation (SpO2) >94% RA N.B. The CST protocol
inclusion criteria will take precedence over the master protocol inclusion criteria
CST-2 Inclusion Criteria
For the purpose of the EIDD-2801 candidate-specific trial the following inclusion criteria
have been amended from the Master protocol to
Male or female ≥ 60 years old or ≥50 years old with at least one well controlled
comorbidity: cardiovascular disease, chronic lung disease (e.g. COPD, or pulmonary
hypertension), immune deficiency (taking the equivalent of 20 mg prednisone daily
chemotherapy, or immune modulating biologic therapies), diabetes (treated with insulin or
Additional criteria specific to this candidate are
oral medications), BMI≥30, or hypertension requiring medication with laboratory confirmed
SARS-CoV-2 infection (PCR)
Women of childbearing potential (WOCBP) and male patients who are sexually active with
WOCBP must agree to use two effective methods of contraception, one of which should be
highly effective (as outlined in the protocol). For women, from the first administration of
trial treatment, throughout trial and up to 50 days after the last follow up visit (50 days
after day 29) and for men with female partners of child bearing potential, from the first
administration until 100 days after last follow up visit (100 days after day 29)
Group B (mild-moderate disease): Ambulant with the following characteristics peripheral
capillary oxygen saturation (SpO2) >94% RA (NB this differs to the Master Protocol which
also includes hospitalised patients in this group)
Has signs or symptoms of COVID-19 that began within 5 days of the planned first dose of
study drug
Is in generally good health (except for current respiratory infection) and is free of
uncontrolled chronic conditions
Is willing and able to comply with all study procedures and attending clinic visits
through the 4th week
Has someone, aged ≥ 16 living in the same household during the dosing period

Exclusion Criteria

Pregnant or breast feeding
Anticipated transfer to another hospital which is not a study site within 72 hours
Allergy to any study medication
Patients participating in another CTIMP trial
CST-2 Exclusion Criteria
Additional criteria specific to this candidate are
Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >5 times the
upper limit of normal (ULN)
Stage 4 severe chronic kidney disease or requiring dialysis (i.e., estimated
glomerular filtration rate <30 mL/min/1.73 m^2)
Patients taking other prohibited drugs (as outline in CST protocol) within 30 days or
times the half-life (whichever is longer) of enrolment
N.B. The CST protocol exclusion criteria will take precedence over the master protocol
exclusion criteria
Has a febrile respiratory illness that includes signs of pneumonia, or requires
hospitalization, oxygenation, mechanical ventilation, or other supportive modalities
Has a platelet count less than 50x10^9/L, or lymphocytes less than 0.2x10^9/L
haemoglobin less than 10 g/dL, or has a disorder of the hematologic system including
anaemic disorder or other blood dyscrasia, cancer of the hematologic system, history
of bone marrow transplant, or other significant hematologic disease at screening
Is experiencing adverse events or laboratory abnormalities that are Grade 3 or above
based on the CTCAE scale
Has clinically significant liver dysfunction or renal impairment
Has history of Hepatitis C infection or concurrent bacterial pneumonia
Has received an experimental agent (vaccine, drug, biologic, device, blood product, or
medication) within 30 days prior to the first dose of study drug
In the opinion of the investigator, has significant end-organ disease as a result of
relevant comorbidities: chronic kidney disease, congestive heart failure, peripheral
vascular disease including diabetic ulcers
Has a SaO2<95% by oximetry or has lung disease that requires supplemental oxygen
Has any condition that would, in the opinion of the investigator, put the patient at
increased risk for participation in a clinical study
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note